相关实验视频

Updated: Jun 25, 2025

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

新型combretastatin A-4类似物-设计,合成,以及抗增殖和抗图布林活性

Marta Jędrzejczyk¹, Benedetta Morabito², Barbara Żyżyńska-Granica³

¹Department of Medical Chemistry, Faculty of Chemistry, Adam Mickiewicz University, Uniwersytetu Poznańskiego 8, 61-614 Poznań, Poland.

Molecules (Basel, Switzerland)

|May 25, 2024

概括

新的combretastatin A-4类似物被合成并测试了抗瘤特性. 化合物8和20显示出显著的细胞毒性活性和细胞循环停止,与素结合相关.

科学领域:

药用化学医学化学
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

康布雷塔斯塔丁 (combretastatins) 是一种来自*Combretum caffrum*的基,它可以抑制氨酸的聚合,阻止细胞分裂.
康布雷塔斯A-4是一种强大的线粒酶抑制剂,具有已证明的抗瘤潜力.
需要新的类似物来探索结构-活动关系并提高疗效.

研究的目的:

合成新的combretastatin A-4类似物与碳酸,和胺基组.
评估这些类似物对各种瘤细胞系的细胞毒性活性.
研究作用机制,包括细胞循环效应和素相互作用.

主要方法:

康贝拉斯塔丁A-4类似物的化学合成.
在体外细胞毒性测试中使用硫胺B测定.
细胞循环分析 (G0 / G1 停止) 和体外氨酸聚合试验.
计算对接和结合能量分析与人类管氨酸同型.

主要成果:

合成了几种新型类似物,并对细胞毒性活性进行了选.
化合物8和20对测试的瘤细胞系表现出显著的细胞毒性.
这些化合物以度依赖的方式诱导G0/G1细胞循环停止.
化合物8和20作为氨酸聚合增强剂.
在计算的结合能和实验IC50值之间观察到强烈的相关性.

结论:

新型康培拉酸A-4类比体现出强大的细胞毒性和细胞循环停止特性.
化合物8和20为进一步抗癌药物开发提供了有希望的线索.
计算建模有助于理解结构-活性关系,并根据氨酸同型结合预测有效性.

关键词:

它们具有抗增殖活性.结合能量是一种约束能量.科尔奇辛的结合部位作为一种常见的药物,combretastatin.体向剂是一种向剂.

更多相关视频

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...